"The
Report PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast
and Market Analysis to 2022 - Event-Driven Update provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Summary
Non-Small
Cell Lung Cancer (NSCLC) is the most common lung cancer, and the
second-most common cancer in men and women. Historically, the
treatment paradigm has centered around chemotherapy. However, the
launch of targeted therapies for patients with specific biomarkers
has begun to fragment the NSCLC treatment landscape into smaller
niche patient populations. Over the forecast period, this trend will
continue with the launch of multiple new drugs in several new drug
classes to address the high unmet need among NSCLC patients, and
provide new treatment options for previously underserved populations.
This
Event-Driven Update was published in response to major events that
occurred during the first quarter of 2014 that will result in the
failure of several premium-priced agents to launch in the US and
global markets during the forecast period. These agents include
Pfizers dacomitinib and Boehringer Ingelheims nintedanib in the US,
and Roches MetMab (onartuzumab) and GSKs MAGE-A3 immunotherapy in the
global markets.
View Report At
:http://www.marketresearchreports.biz/analysis/210566
Highlights
Key Questions Answered
-
The NSCLC market will become increasingly crowded during the
forecast. How will the first and second lines of therapy be impacted
by the launch of new therapies?
-
How will the failure of dacomitinib and nintedanib to launch in the
US affect global market growth? What effect will the failure to
launch of MetMab (onartuzumab) and the MAGE-A3 immunotherapy in the
nine major markets have on global market dynamics?
-
How will the increasing stratification of patient populations by
biomarkers affect the treatment landscape?
-
The unmet needs of NSCLC patients are relatively high. What unmet
needs will be addressed by the launch of new treatment options during
the forecast period? What unmet needs will remain?
-
How will Alimta, Avastin, Iressa and Tarceva patent expirations
affect overall market growth during the forecast?
-
How will increasing cost consciousness among European reimbursement
authorities affect market growth in the 5EU?
Key Findings
-
Launch of emerging pipeline therapies will result in more patients
receiving premium-priced drugs in the first and second lines of
therapy, and market growth in the US and Japan. However, the US and
nine major markets will be negatively affected by the failure of
premium-priced agents including dacomitinib, nintedanib, MetMab and
MAGE-A3 to launch during the forecast period.
-
Despite the launch of remaining premium-priced therapies such as Eli
Lillys necitumumab and BMS nivolumab, the NSCLC market will shrink in
the 5EU. This will be primarily due to the reduction in number of new
premium-priced agents that will launch as well as the loss of patent
protection for most of the major branded therapies as well as
increasing cost pressures from European reimbursement authorities.
-
The Indian and Chinese markets will continue to be difficult to
penetrate. Many emerging pipeline therapies will not launch in these
markets, especially expensive biologic therapies. Generic
competition, regulatory hurdles and high cost of therapies will be
major barriers to growth in these markets.
-
BMSs nivolumab will emerge as the overall market leader in 2022,
launching first in the second-line segment in 2015 and expanding into
the first-line segment in 2019. Uptake will be driven by the drugs
promising clinical efficacy in both squamous and non-squamous
patients and strong safety profile.
-
After Iressa and Tarceva lose patent protection in 2019 and 2020,
respectively, Boehriger Ingelheims Gilotrif (afatinib) will emerge as
the leading therapy for EGFR-positive patients. Gilotrifs market
position will be driven by high uptake in the second-line segment.
-
Pfizers Xalkori will lose ALK-positive patient share to Novartis
ceritinib (LDK378) in the second-line segment. However, Xalkori will
continue to be the patient share leader in the more lucrative first
line setting and will maintain the overall sales leadership over
LDK378 throughout the forecast.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/210566
Scope
-
Overview of NSCLC, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines.
-
Annualized NSCLC therapeutics market revenue, annual cost of therapy
and treatment usage pattern data by patient segment forecast from
2012 to 2022.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the NSCLC therapeutics market.
-
Pipeline analysis: comprehensive data assessing emerging trends and
mechanisms of action under development for different lines of
therapy. The most promising 13 candidates in Phase III development
are profiled.
-
Analysis of the current and future market competition in the global
NSCLC market. Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to
provide qualitative analysis of its implications.
Reasons to buy
-
Develop business strategies by understanding the trends shaping and
driving the global NSCLC therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global NSCLC therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analyzing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Forecast drug sales in the global NSCLC therapeutics market from
2012-2022.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment